Drug intelligence / Profile preview

LPM3770164

Development stage: Phase 2
Lead developer: Luye Pharma
Modality: Small Molecules
Administration: Oral

Overview

LPM3770164 is an investigational small molecule drug that acts as a selective inhibitor of vesicular monoamine transporter 2 (VMAT2). By inhibiting VMAT2, it reduces the uptake of monoamines (such as dopamine) into synaptic vesicles, thereby modulating neurotransmitter release. The drug is being developed primarily for the treatment of tardive dyskinesia and Huntington's disease. LPM3770164 was initially developed by Shandong Luye Pharmaceutical and is currently in Phase 2 clinical trials for tardive dyskinesia and Phase 1 for Huntington's disease[1][6][7]. It is administered orally in sustained-release tablet form.

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)VMAT2 (Vesicular monoamine transporter 2)

Beyond the preview

Go deeper on LPM3770164.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPM3770164.

Explore the full profile